Recursos disponibles para el tratamiento del cáncer de mama en México

Mohar, Alejandro; Bargalló, Enrique; Ramírez, Ma. Teresa García; Lara, Fernando; Beltrán-Ortega, Arturo

doi:10.1590/s0036-36342009000800017

Cited by 34 publications

(44 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of the 204 radio-oncologists identified 5 , the survey was applied only to those in whom contact by e-mail was possible (total, 167 radio-oncologists); 68 completed the survey, for a response rate of 40.7%.…”

Section: Results Target Survey Populationmentioning

confidence: 99%

“…Breast cancer mortality in Mexico has increased from 58/100,000 women in 1998 to 67/100,000 in 2008. as of 2006, BC was the leading cause of cancer death in women, representing a shift from cervical cancer and accounting for 14% of all cancer cases 5,6 .…”

Section: Improvement Of Symptoms With Radiation Therapy For Palliativmentioning

confidence: 99%

“…Mortality for BC has been trending upward in Mexico for several decades [5][6][7] . given the increased frequency of advanced disease at diagnosis in Mexico and the lack of radiotherapy units, 85% of cases attended in third level reference hospitals undergo mastectomy 1 .…”

Section: Introductionmentioning

confidence: 99%

“…Radiation therapy also has favorable results in palliative care, relieving symptoms earlier and demonstrating functional recovery in a more efficient manner compared to other therapies. additionally, palliative radiotherapy for bone metastasis in one fraction treatment is cost-effective and better than pain medication and chemotherapy [5][6][7]10 .…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Radiotherapy for Metastatic Breast Cancer in Mexico: Results from the 2015 National Survey

Álvarez-Águila¹,

Cook²,

Prada

et al. 2017

RIC

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Results Target Survey Populationmentioning

confidence: 99%

Section: Improvement Of Symptoms With Radiation Therapy For Palliativmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Radiotherapy for Metastatic Breast Cancer in Mexico: Results from the 2015 National Survey

Álvarez-Águila¹,

Cook²,

Prada

et al. 2017

RIC

Self Cite

View full text Add to dashboard Cite

show abstract

“…In Mexico, with a population of over 100 million, between 2 and 4 women per 100,000 die from breast cancer; an increment of 16,500 new cases are estimated for 2020 [1] [2]. Therapy with cyclophosphamide and adriamycin as chemotherapeutic agents is one of the most widely used to treat breast cancer.…”

Section: Introductionmentioning

confidence: 99%

Genotoxic and Cytotoxic Damage by Cyclophosphamide and Adriamycin as a Response to Treatment in Breast Cancer Patients: Pilot Study

Garibay-Garcia¹,

Mejia-Sanchez²,

Ramírez-Sanjuan³

et al. 2015

JCT

View full text Add to dashboard Cite

The aim of this study was to evaluate the genotoxicity induced by cyclophosphamide-adriamycin treatment in breast cancer patients through the frequencies of Sister Chromatid Exchange (SCE), Replication Index (RI), Mitotic Index (MI) and Cell Proliferation Index (CPI) and to study the possible association between biomarkers of genotoxicity and the early response to treatment. The frequencies were obtained before and immediately after therapy from 17 patients with breast cancer (p < 0.001). Response to treatment was assessed after two years resulting in 12 patients in a state of remission. MI and CPI had high values after treatment in women with active cancers compared to those in a state of remission, however there were not significant differences. Conclusions: It is possible that MI y CPI biomarkers can serve as indicators for early assessment of treatment with cyclophosphamide-adriamycin. It should be noted that these are preliminary results and further study is necessary.

show abstract

Overweight and obesity as poor prognostic factors in locally advanced breast cancer patients

Arce-Salinas

Aguilar-Ponce

Villarreal‐Garza

et al. 2014

Breast Cancer Res Treat

View full text Add to dashboard Cite

Obesity and overweight are established risk factors for the development of breast cancer. They are also associated with poor prognosis for higher risk of disease recurrence and lower overall survival (OS). The aim of this study was to evaluate the influence of overweight and obesity in OS in patients with locally advanced breast cancer (LABC) treated with neoadjuvant chemotherapy. This is a retrospective analysis that included 819 patients diagnosed with LABC between January 2004 and December 2008. The patients were treated with neoadjuvant chemotherapy (NAT) based on anthracyclines, taxanes, or both, followed by surgery. For comparison, patients were divided into the normal weight (NW) group or the overweight/obesity (OW/OB) group. The prevalence of overweight/obesity was 74 %. General characteristics of the patients, including age, tumor size, clinical stage, nuclear grade, hormone receptors, and HER2 expression, were similar between both groups. At a median follow-up of 28 months, we found a statistically significant difference in OS between the two groups, achieving a 91.5 % in NW patients versus 85.9 % in the OW/OB group (P = 0.050). Cox multivariate analysis demonstrated that obesity was an independent factor for poor prognosis, with a hazard ratio of 1.79 (95 % CI (Confidence Interval) 1.09-2.96; P = 0.022). This is the first Mexican study that confirms the role of OW/OB as a risk factor for poor outcome among patients with LABC. Obesity in our country is a public health problem and requires strong preventive intervention strategies for its control, especially among patients diagnosed with breast cancer.

show abstract

Recursos disponibles para el tratamiento del cáncer de mama en México

Cited by 34 publications

References 23 publications

Radiotherapy for Metastatic Breast Cancer in Mexico: Results from the 2015 National Survey

Radiotherapy for Metastatic Breast Cancer in Mexico: Results from the 2015 National Survey

Genotoxic and Cytotoxic Damage by Cyclophosphamide and Adriamycin as a Response to Treatment in Breast Cancer Patients: Pilot Study

Overweight and obesity as poor prognostic factors in locally advanced breast cancer patients

Contact Info

Product

Resources

About